Skip to main content
Journal of the American Society of Nephrology : JASN logoLink to Journal of the American Society of Nephrology : JASN
editorial
. 2026 Sep 17;37(11):2367–2369. doi: 10.1681/ASN.0000001253

β-Blockers in Hemodialysis

Does Dialyzability Matter?

Bróna M Moloney 1, Finnian R Mc Causland 1,✉
PMCID: PMC13743005  PMID: 42752512

Patients receiving maintenance hemodialysis are at a high risk of adverse outcomes. The risk of death is the highest in the first few months after initiation, thereafter averaging around 18% per year, with approximately half dying by 3 years.1 Although there has been major progress in reducing cardiovascular outcomes in the general population, cardiovascular morbidity and mortality remain unacceptably high among patients receiving hemodialysis, with approximately 40% dying from cardiovascular causes.1 Despite this high risk, there is a relative paucity of large cardiovascular outcomes trials in the hemodialysis population. Moreover, in those that have been completed, therapies with proven efficacy to lower risk in other populations have not translated into clear benefits in hemodialysis (e.g., statins,2 spironolactone3). Some point to a lack of effect on hemodialysis-specific nontraditional risk factors in an attempt to explain such disappointing results, but even targeting secondary hyperparathyroidism with cinacalcet did not lower cardiovascular outcomes in this population.4 A recent welcome exception was the Protection against Incidences of Serious Cardiovascular Events Study with Daily Fish Oil Supplementation in Dialysis Patients trial, which reported impressive cardiovascular benefits for n-3 polyunsaturated fatty acids (fish oil) versus corn oil placebo5; however, some have called for confirmatory evidence,6 particularly in the US population, before recommending widespread implementation of this therapy.

In addition to the high burden of cardiovascular disease, there is an almost universal history of hypertension among patients receiving hemodialysis. As such, it is perhaps no surprise that β-blockers are among the most commonly prescribed cardiovascular medications (approximately 60%).1 However, although β-blockers carry a class 1a recommendation for use in patients with heart failure with reduced ejection fraction (EF <50%) and following a myocardial infarction, the trials generating the evidence for these recommendations did not include patients receiving hemodialysis. Furthermore, β-blockers are not endorsed as first-line antihypertensive agents, while the trial-level evidence base for BP targets among patients receiving hemodialysis is almost nonexistent. Despite these caveats, β-blockers are used extensively in combination with other drugs in the hemodialysis population, presumably in part to treat high BP. Indeed, β-blocker use has some biologic rationale, as they may offer therapeutic advantages over antihypertensive agents by attenuating β-adrenergic signaling in a hemodialysis population characterized by heightened sympathetic activity.7 However, whether this rationale translates into a meaningful reduction in cardiovascular outcomes among patients receiving hemodialysis remains unknown.

Trial-level evidence evaluating β-blockers with clinical outcomes in the hemodialysis population is also limited, with randomized studies largely focused on structural and mechanistic end points rather than being powered to detect differences in all-cause mortality, cardiovascular mortality, or major adverse cardiac events (MACE). For example, in a small randomized trial of maintenance hemodialysis patients with dilated cardiomyopathy (N=114; left ventricular EF <30%), carvedilol was associated with improvements in left ventricular structure and function compared with placebo (benefits were sustained at 2-year follow-up, with fewer cardiovascular events and deaths reported in the carvedilol group).8 In an open-label trial (N=200), patients with left ventricular hypertrophy and hypertension receiving hemodialysis were randomized to atenolol or lisinopril, each administered three times weekly after dialysis, with the primary outcome of change in left ventricular mass index. However, the trial was terminated early because of a higher frequency of cardiovascular outcomes in the lisinopril group, while no between-drug differences in left ventricular mass index were noted.9 The design of β-blockers trials in hemodialysis is further complicated by differences in pharmacokinetics, dialyzability, and cardioselectivity of medications in this class, while hemodialysis prescriptions (e.g., membrane type, session duration), residual kidney clearance, and timing of administration relative to the dialysis session may introduce additional variability. It is therefore not surprising that the more nuanced question of differential effects of β-blocker dialyzability on cardiovascular outcomes remains uncertain. To address this evidence gap, in this issue of JASN, Etemadi et al. report a comparative effectiveness study of dialyzable versus nondialyzable β-blockers and cardiovascular outcomes among patients newly initiated on hemodialysis,10 addressing an important question for which clinical equipoise remains.

To approximate the causal inference of a randomized controlled trial, the authors used a target trial emulation approach using United States Renal Data System data (restricting to patients aged ≥67 years at hemodialysis initiation and to those with Medicare coverage). As most patients were already prescribed a β-blocker, this was a prevalent user design, meaning the target trial question relates to a participant switching to the assigned therapy, if one was not already taking it (i.e., dialyzable versus nondialyzable β-blocker, rather than β-blocker versus not). An instrumental variable approach was used to emulate quasi-randomized treatment groups. An instrumental variable is a factor/variable that influences the treatment choice but should not affect the outcome, except through the treatment—in this case, the authors leveraged regional prescribing preferences (using modeling approaches to identify a quartile of participants most likely to be prescribed a dialyzable β-blocker and a quartile most likely to be prescribed a nondialyzable β-blocker). They verified three core instrumental variable assumptions: relevance (instrument must influence the treatment), independence (instrument should be independent of factors that affect the outcome), and exclusion restriction (instrument affects the outcome only through the treatment). Outcomes were ascertained using claims-based definitions (myocardial infarction and stroke using International Classification of Diseases 9/10 codes; mortality via the ESRD Death Notification form), with several sensitivity analyses, including adherence and a stable-exposure cohort.

The main results were notable for an 18%, 15%, and 10% lower risk of MACE for the nondialyzable β-blocker group, compared with the dialyzable β-blocker group, at 180 days, 1 year, and 3 years of follow-up, respectively. Consistent patterns were observed for the individual components of the composite MACE outcome. Effects estimates were directionally similar, but attenuated, in conventional adjusted Cox models. Notably, using the instrumental variable approach, nondialyzable versus dialyzable β-blocker estimates were not associated with prespecified negative control outcomes, whereas the treatment assignment was associated with three of the four negative control outcomes in Cox regression approaches (perhaps suggesting greater residual confounding with conventional Cox methods).

These results contrast with some previous studies that found associations in favor of dialyzable β-blockers, which the authors postulated could be explained by differences in incident versus prevalent populations, with a greater risk of intradialytic hypotension and its attendant sequelae in hemodialysis patients of longer vintage.10 Differences in methodologic approaches may have also contributed to differences from previous reports, which again are thoughtfully discussed by the authors. For example, an important point in the interpretation of instrumental variable analyses is that the estimate primarily identifies the treatment effect among compliers, i.e., patients whose treatment choice is changed by the instrument. Hence, rather than the effect on outcomes if every patient received a nondialyzable β-blocker instead of a dialyzable one, the estimates more closely address the effect of nondialyzable β-blockers versus dialyzable β-blockers among patients whose treatment choice is influenced by prescribing preferences. Moreover, although the treatment assignment intervention was designed to address β-blocker dialyzability, the treatment group comparison largely comprised carvedilol versus metoprolol, raising the possibility that the observed associations reflect other drug-specific characteristics, rather than dialyzability alone. There are also recognized limitations of claims-based exposure and outcome ascertainment and limitations related to generalizability beyond the characteristics of the included participants. Furthermore, the present analyses did not account for important adverse events relevant to the hemodialysis procedure itself, including intradialytic hypotension and bradycardia, nor patient-reported medication side effects of relevance to this population, such as erectile dysfunction and fatigue. Thus, it is difficult to holistically assess any potential cardiovascular benefit without knowing more information about the potential downsides of such therapies. Perhaps most importantly, despite the robust methods used, Etemadi et al. are to be commended for their transparency in acknowledging that their findings do not establish definitive causality.

Limitations aside, there are several additional findings of clinical interest. Most cardiovascular events occurred within the first 6 months after hemodialysis initiation, confirming this as a high-risk period and a potentially critical window for intervention in contemporary practice. The most pronounced estimates of benefit were observed during this early period, raising the possibility that any relative benefits of different β-blocker therapies may change with dialysis vintage. For example, early following hemodialysis initiation, when sympathetic activation is heightened, cardio-selective β1-blockade may reduce cardiac sympathetic overactivity, with minimal effects on vascular tone. However, with progressive impairment of baroreflex function over time, the additional α-1 blocking activity of agents such as carvedilol could increase susceptibility to intradialytic hypotension (potentially offsetting the benefits of sympathetic attenuation). Of course, such hypotheses require prospective testing and further study.

Before addressing the clinical implications of this study, it would be remiss not to note the broader issue: whether current indications for β-blockers, extrapolated from nonhemodialysis populations, are applicable to patients receiving maintenance hemodialysis. This is a highly relevant question but not addressed by the present report. Focusing on the data from Etemadi et al., should these results influence our approach to prescribing nondialyzable versus dialyzable β-blockers in incident patients on hemodialysis? In our opinion, we would not immediately change prescribing practices based on the available evidence to date. Rather, these findings should be considered as hypothesis-generating and catalyze efforts to address the residual burden of cardiovascular disease among hemodialysis patients by using randomized controlled trials. Although conventional trials in this population face substantial recruitment challenges, recent examples have shown that they are possible.3,5 As a community of stakeholders in the care of patients receiving hemodialysis, we owe it to our patients and their families to perform such studies.

Supplementary Material

jasn-37-2367-s001.pdf (1.4MB, pdf)

Acknowledgments

Dr. Moloney reports funding from the ASN Foundation for Kidney Research (Ben J. Lipps Postdoctoral Fellowship grant 2025), awarded by Kidney Cure. The content of this article reflects the personal experience and views of the author and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or JASN. Responsibility for the information and views expressed herein lies entirely with the author.

Footnotes

See related article, “Nondialyzable versus Dialyzable β-Blockers in Hemodialysis: A Target Trial Emulation Study,” on pages 2506–2516.

Disclosures

Disclosure forms, as provided by each author, are available with the online version of the article at https://links.lww.com/JSN/G6.

Author Contributions

Writing – original draft: Bróna M. Moloney.

Writing – review & editing: Finnian R. Mc Causland, Bróna M. Moloney.

Funding

None.

References

  • 1.United States Renal Data System . United States Renal Data System Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS; 2024. [Google Scholar]
  • 2.Sun L, Zou L, Chen M, Liu B. Meta-analysis of statin therapy in maintenance dialysis patients. Ren Fail. 2015;37(7):1149–1156. doi: 10.3109/0886022X.2015.1061871 [DOI] [PubMed] [Google Scholar]
  • 3.Pyne L Rossignol P Giles C, et al. Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2025;406(10505):811–820. doi: 10.1016/S0140-6736(25)01153-5 [DOI] [PubMed] [Google Scholar]
  • 4.Chertow GM Block GA Correa-Rotter R, et al. EVOLVE Trial Investigators.; Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–2494. doi: 10.1056/NEJMoa1205624 [DOI] [PubMed] [Google Scholar]
  • 5.Lok CE Farkouh M Hemmelgarn BR, et al.; PISCES Investigators. Fish-oil supplementation and cardiovascular events in patients receiving hemodialysis. N Engl J Med. 2026;394(2):128–137. doi: 10.1056/NEJMoa2513032 [DOI] [PubMed] [Google Scholar]
  • 6.Mazón-Ruiz J, de Cos Gomez M, González Bores P, Corral P. Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurement. Clin Kidney J. 2026;19(5):sfag118. doi: 10.1093/ckj/sfag118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905–1913. doi: 10.1038/sj.ki.5001835 [DOI] [PubMed] [Google Scholar]
  • 8.Cice G Ferrara L D’Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy A prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–1444. doi: 10.1016/s0735-1097(03)00241-9 [DOI] [PubMed] [Google Scholar]
  • 9.Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014;29(3):672–681. doi: 10.1093/ndt/gft515 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Etemadi A, Liu S, Winkelmayer WC, Montez-Rath ME, Chang TI. Nondialyzable versus dialyzable β-blockers in hemodialysis: a target trial emulation study. J Am Soc Nephrol. 2026;37(11):2506–2516. doi: 10.1681/ASN.0000001147 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the American Society of Nephrology : JASN are provided here courtesy of American Society of Nephrology

RESOURCES